IP Library Granted Patent US 11,000,590
Granted Patent B2
US 11,000,590 · App. 16/432,825 · Granted May 11, 2021

Virus-PCION complex having enhanced antitumor effect by using electromagnetic field

Inventors: Chae Ok Yun (Seoul, KR); Joung-Woo Choi (Seoul, KR)
Assignee: GENEMEDICINE CO., LTD.
A61K41/00A61K9/5146A61K9/5169A61K41/0052A61K47/60A61K47/645A61K47/6923A61K47/6941C12N7/00C12N15/86A61K35/761C12N2710/10332C12N2710/10343
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,000,590
App. No.
16/432,825
Granted
May 11, 2021
Kind
B2
Abstract

The present disclosure relates to a composition for transduction of a virus in a cell by using a crosslinked product of PEGylated magnetic nanoparticles and catechol grafted poly-L-lysine by application of an external magnetic field. When the composition is used, a virus may be delivered into cells more rapidly and efficiently than in intracellular uptake of a virus by CAR-mediated endocytosis.

Claims (9)

1. A method of treating cancer, the method comprising:

administering a complex comprising: (a) magnetic nanoparticles cross-linked with catechol grafted poly-L-lysine and having PEGylated surfaces; and (b) an oncolytic andenovirus to an individual in a presence of a magnetic field,

wherein a molar ratio of the magnetic nanoparticles to the oncolytic andenovirus in the complex ranges from about 1:1×10 6 to about 1:8×10 7 .

2. The method of claim 1 , wherein the magnetic nanoparticles comprise one selected from the group consisting of maghemite (Fe 2 O 3 ), magnetite (Fe 3 O 4 ), and mixtures thereof.

3. The method of claim 1 , wherein in the catechol grafted poly-L-lysine, a degree of substitution of a catechol functional group with respect to the poly-L-lysine ranges from about 5 to about 30.

4. The method of claim 1 , wherein the magnetic nanoparticles and the catechol grafted poly-L-lysine are mixed in a weight ratio of about 10:1 to about 1:5.

5. The method of claim 1 , wherein the complex exhibits decreased liver tropism by application of an external MGF.

6. The method of claim 1 , wherein the cancer is selected from the group consisting of stomach cancer, lung cancer, breast cancer, ovarian cancer, liver cancer, bronchial cancer, nasopharyngeal cancer, laryngeal cancer, pancreatic cancer, bladder cancer, colon cancer, and cervical cancer.

7. The method of claim 1 , wherein the cancer comprises a coxsackievirus and adenovirus receptor (CAR) negative tumor.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 28, 2020
From: INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY
To: GENEMEDICINE CO., LTD.
Reel/Frame 052511/0457 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2019
From: YUN, CHAE OK; CHOI, JOUNG-WOO
To: INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY
Reel/Frame 050001/0056 →
Priority Claims (1)
KR 10-2016-0030514 · Mar 14, 2016 · national
Continuity (2)
Division 15458685 · Mar 14, 2017
Related Publication 20190298831A1 · Oct 3, 2019